Melatonin May Lower Self-Harm Risk in Young People, Especially Girls
A observational study found the risk of self-harm increased in the months preceding melatonin prescription and decreased thereafter.
Category: Prescription Drugs
Prescription Drugs
Latest
Prescription Drugs
Latest
FDA Data Captures Dosing Errors with Twice-Nightly Oxybates for Narcolepsy
Investigators affiliated with Avadel Pharmaceuticals plc published a paper describing the risk of accidental dosing errors with oxybate.
Prescription Drugs
Latest
New Studies: Sleep Apnea Pill Shows Durability of Effect & Improved Quality of Life in Mild to Severe OSA
The randomized, placebo-controlled segment of the study showed that AD109 had a statistically significant and clinically meaningful difference from placebo after a single dose in the patients’ hypoxic burden.
Don’t Light the Fuse of Restless Legs Syndrome with Dopamine Agonists
Twenty percent of restless legs syndrome patients are already on higher-than-recommended doses of dopamine agonists, says John Winkelman, MD, PhD.
Read More
Axsome Therapeutics to Acquire Sunosi from Jazz Pharmaceuticals
The acquisition of Sunosi adds a high-potential commercial asset to Axsome’s late-stage neuroscience portfolio.
Read MoreAzurity Pharmaceuticals Acquires Arbor Pharmaceuticals
Azurity Pharmaceuticals Inc has acquired Arbor Pharmaceuticals Inc, marketers of the restless legs syndrome drug Horizant.
Read MoreNSAIDS May Limit Passage of Narcolepsy Medication Gamma Hydroxybutyric Acid to the Brain
Previous studies completed by the UB researchers found that the NSAIDs ibuprofen and ketoprofen also affected the movement of GHB in the body.
Read More
Somyrst, FDA-authorized Digital Insomnia Therapy, Now Has formulary Availability at OptumRx
OptumRx will offer and administer standard pharmacy benefit coverage for members who choose to add the product to their formularies.
Read MoreBenzodiazepines & Z-Drugs Up Death Risk When Taken with Opioids
Benzodiazepines, including brand names such as Restoril, Ativan, and Halcion and the “z-drugs”, a type of medication known more commonly under names like Ambien, Lunesta, and Sonata, are among the most frequently prescribed medications for older adults.
Read More
Pear Therapeutics’ Somryst Added to Serve You Rx’s Formularies
Serve You Rx will provide prescription benefit coverage of Somryst to their members as a standard offering on all formularies.
Read More
FDA Grants Orphan Drug Status to Xywav, Citing “Greatly Reduced Chronic Sodium Burden Compared to Xyrem”
The FDA also published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness associated with narcolepsy.
Read More
Purdue Pharma Studies Sleep Quality Outcomes of Methylphenidate HCl for ADHD
“As some adult patients with ADHD experience insomnia, there is considerable individual variability, and an identified need for more data on the effect of prescription ADHD stimulant medications on sleep.”
Read More
Two Poster Presentations Include New Post-Hoc Analyses That Highlight Clinical Effectiveness of WAKIX
“The analyses include both a traditional approach to presenting efficacy data, as well as one that underscores the clinical relevance of the findings, using [number needed to treat] and effect sizes to capture overall clinical benefit.”
Read MoreJazz Pharmaceuticals Shares Results from Sleep Medicine Research & Therapy Development
Thirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
Read More
Long-Term Use of Prescription Meds for Insomnia Not Linked to Better Quality Sleep
There was no difference in sleep quality or duration between those who did and didn’t take these meds for 1 to 2 years, the findings show.
Read MoreWAKIX Data Presented to Mental Health Professionals at APA Annual Meeting
Sleep disorders are highly comorbid with a multitude of psychiatric disorders and narcolepsy can have a significant impact on a person’s daily functioning, which may greatly affect their social, emotional and psychological well-being, and quality of life.
Read More
Jazz Pharmaceuticals Presents Phase 3 Results of Xywav in Idiopathic Hypersomnia
The AAN presentation further quantifies the previously reported Phase 3 top-line results.
Read More
What Region Is Most Associated with Fracture-Associated Prescription Drug Use?
Many commonly prescribed drugs—such as some sleep aids—are known to carry an increased risk of breaking a bone, by increasing falls, weakening bones, or both.
Read More